Cabaletta Bio prices $150M stock offering to fund autoimmune cell therapy development

Cabaletta Bio, a clinical-stage biotech company focused on autoimmune disease therapies, announced a $150 million underwritten offering of 51.7 million common shares at $2.90 each. The funds will support the development and launch of their targeted cell therapies, including their lead investigational therapy, rese-cel. The offering includes participation from existing and new investors such as Bain Capital Life Sciences and Eli Lilly. The transaction is expected to close around May 5, 2026, pending customary conditions.